Cmp Dev Llc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for CMP DEV LLC, and what generic alternatives to CMP DEV LLC drugs are available?
CMP DEV LLC has four approved drugs.
There are twelve US patents protecting CMP DEV LLC drugs.
There are fourteen patent family members on CMP DEV LLC drugs in nine countries and thirty-seven supplementary protection certificates in ten countries.
Summary for Cmp Dev Llc
| International Patents: | 14 |
| US Patents: | 12 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Cmp Dev Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 11,253,474 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | RX | Yes | Yes | 11,395,828 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | RX | Yes | Yes | 11,491,166 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | RX | Yes | Yes | 10,493,083 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cmp Dev Llc | POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 212121-001 | Sep 19, 2019 | RX | Yes | Yes | 10,632,150 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cmp Dev Llc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017075463 | ⤷ Try a Trial |
| Canada | 3086881 | ⤷ Try a Trial |
| Singapore | 11202006080S | ⤷ Try a Trial |
| Morocco | 43132 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2019130052 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cmp Dev Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0443983 | 2007C/043 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222 |
| 2101777 | 122016000039 | Germany | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120 |
| 0740668 | 03C0017 | France | ⤷ Try a Trial | PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112 |
| 1441735 | 2008/010 | Ireland | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220; |
| 2101777 | CA 2016 00024 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
